• Sichuan Cancer Hospital, Chengdu 610041, China;
LU Jin, Email: jinlu6457@sina.com
Export PDF Favorites Scan Get Citation

目的:評價奈達鉑聯合氟脲嘧啶/四氫葉酸治療晚期復發耐藥食管癌的療效及不良反應。方法:30例晚期復發耐藥食管癌均經病理學或細胞學確診。奈達鉑100mg/㎡,靜脈滴注,第1天;氟脲嘧啶500mg/㎡,靜脈滴注,維持6~8小時,第1~5天; 四氫葉酸200mg,靜脈滴注,第1~5天,21天為一周期,連續用2周期后評價療效及不良反應。結果:30例均完成2個周期以上化療,共接受86周期化療,全部病例均可評價療效及不良反應。無CR病例,PR 13例(43.3%),SD 7例(23.3%),PD 10例(33.3%),有效率為43.3%,TTP 4.0月,MST8.3月。不良反應主要是骨髓抑制,惡心、嘔吐,全組無IV度不良反應。結論:奈達鉑聯合氟脲嘧啶/四氫葉酸治療晚期復發耐藥食管癌有確切療效,不良反應輕,耐受性好,值得臨床進一步推廣應用。

Citation: YIN Xude,CHEN Ping,LU Jin,et al.. Clinical Study of Nedaplatin plus 5Fluorouracil/Folinic Acid for the Treatment of Advanced Esophageal Cancer. West China Medical Journal, 2009, 24(6): 1408-1409. doi: Copy

Copyright ? the editorial department of West China Medical Journal of West China Medical Publisher. All rights reserved